Can a pancreatic hormone be used to treat pancreatogenic diabetes?

Not Applicable

• Conditions: Pancreatogenic Diabetes; Nutritional, Metabolic, Endocrine

• Registration Number: ISRCTN62158841
• Lead Sponsor: niversity College London

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-01-28
• Last Update Posted: 29 July 2019
• Study Completion: 2020-04-01

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

1. Aged 18-75
2. Diagnosed with pancreatogenic diabetes (PD) on the basis of:
2.1. WHO 2006 and 2011 criteria defining diabetes mellitus: fasting plasma glucose of =7.0 mmol/L, 2-hour plasma glucose of =11.1 mmol/L after a 75g oral glucose load is consumed, and/or HbA1c =48 mmol/mol.
2.2. Evidence of pancreatic exocrine deficiency: faecal pancreatic elastase levels below local reference limits.
2.3. Abnormal pancreatic morphology on imaging by CT, ultrasound or MRI scanning.
2.4. No evidence of diabetic autoimmune disease, e.g. negative anti-glutamic acid decarboxylase antibodies
2.5. Deficient PP response to a mixed meal tolerance test (<2-fold elevation in PP levels from baseline to peak).
3. Treated with insulin or oral hypoglycaemics for diabetes, doses stable (less than ±10% change in previous 3 months)

Exclusion Criteria

Current pregnancy (positive urinary ß-hCG test)

Study & Design

• Study Type: Interventional
• Study Design: Not specified